28 February 1915

02/27/2021: Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic

01/26/2021: Karyopharm Gets FDA OK of Xpovio in Multiple Myeloma

  • https://m-clark.github.io/mixed-models-with-R/
  • https://stat.ethz.ch/pipermail/r-sig-meta-analysis/2017-December/000434.html
  • https://www.bioconductor.org/help/course-materials/2015/BiocAsia2015/W3-RNASeq.html

01/26/2021: Karyopharm Gets FDA OK of Xpovio in Multiple Myeloma

01/12/2021: An Introduction to Medical Statistics interesting book: https://www-users.york.ac.uk/~mb55/intro/introcon.htm#ci

01/03/2020: https://www.fiercebiotech.com/special-report/glaxosmithkline-top-10-pharma-r-d-budgets-2019 01/01/2020: https://mp.weixin.qq.com/s/riojeB3x8CVBNzWkrvTqrA

COVID19 mRNA vaccine: https://en.wikipedia.org/wiki/Tozinameran COVID19 mRNA vaccine: https://www.mcgill.ca/oss/article/covid-19-critical-thinking-health/reassuring-data-pfizers-covid-19-vaccine

12/30/2020: Trends In US Expedited Review Programs: https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2020/files/article-packs/accelerated-approvals-article-pack-us-coverage.pdf

12/29/2020: Nomenclature_of_monoclonal_antibodies: https://en.wikipedia.org/wiki/Nomenclature_of_monoclonal_antibodies 12/29/2020: Nomenclature_of_drugs: https://en.wikipedia.org/wiki/Drug_nomenclature

12/28/2020: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020 12/28/2020: http://expertmeetingziekenhuisfarmacie.nl/wp-content/uploads/IMS-Health-European-Thought-Leadership-Cell-Gene-Therapy-white-paper-20….pdf

11/30/2020: ‘It will change everything’: DeepMind’s AI makes gigantic leap in solving protein structures. Google’s deep-learning program for determining the 3D shapes of proteins stands to transform biology, say scientists. On protein targets considered to be moderately difficult, the best performances of other teams typically scored 75 on a 100-point scale of prediction accuracy, whereas AlphaFold scored around 90 on the same targets, says Moult. https://www.nature.com/articles/d41586-020-03348-4

11/29/2020, In a recently completed pivotal, clinical efficacy, Phase 3 trial, M-001 failed to demonstrate a statistically significant difference between the vaccinated and placebo groups in reduction of flu illness and severity, and therefore failed to meet both the primary and secondary efficacy endpoints.

Osteoarthritis therapeutics market is expected to grow from USD 6.8 billion in 2019 to reach USD 10.1 billion by 2024, at a CAGR of 8.1%. CAGR Calculator is free online tool to calculate compound annual growth rate for your investment over a time period. To get the CAGR value for your investment, enter the starting value or initial investment amount along with the expected ending value and the number of month or year for which you want to calulate the CAGR. Then, click on calculate button and let the online CAGR calculator calculate the value for you. This will produce the CAGR or compound annual growth rate along with compounded growth chart for your initial investment value.

11/24/2020: FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1.

FDA Approves Sutab (sodium sulfate, magnesium sulfate, and potassium chloride) Tablets for Colonoscopy Preparation Bioinformaticians needed for Genomics Medicine Ireland. GMI is a recently incorporated company leading a large-scale research programme on the human genome to examine the relationship between genetics, health and disease. Our mission is to become a global Center of Excellence for omics and use our scientific strength to understand diseases of genetic origin through analysis and interpretation of the human genome empowered with rich medical and lifestyle data.

We are currently building the next stage of our bioinformatics team (GBT). GBT will analyse the ‘omics data produced at GMI, which currently includes disease cohorts such as IBD, Multiple sclerosis, Alzheimers, rare diseases and cancer. Our work will also focus on ancestry related topics, namely how population genetics can increase the power of disease analysis. GBT will interact with GMI’s very strong IT infrastructure, clinical partnerships and research teams, which facilitate and provide an integrated framework for our bioinformatics analysis. We are building a team of cognitively diverse people, that will feed off each other to find GMI’s analytical solutions, ranging from bioinformaticians; biologists or medical doctors with knowledge of bioinformatics tools; individuals with an IT background with an enthusiasm to apply their knowledge to ’omics.

Essential Qualifications and Knowledge Some of the following: • PhD in Bioinformatics or Genomics • BSc/MSc/PhD in Computer Science/Mathematics/Statistics • Knowledge of rare, neurological, auto-immune or oncological disease research • Knowledge of analysis of genetic causes of disease • Knowledge of statistical genetics • Knowledge of Bioinformatics ‘omics and big data analysis.

Technical Expertise Some of the following: • ’Omic packages such as PLINK, Admixture, Eigensoft, NGSQC, DNAnexus, Ingenuity, Pathway Analysis software, BWA, GATK, SAMtools, ANNOVAR, Peddy • R, Python, Perl, C++, JavaScript • Bioconductor, Biopython, NumPy, SciPy, pandas • Databases and libraries such as PostgreSQL, NoSQL, Hadoop, Spark • Cloud high-performance compute with AWS/GCP • Machine Learning such as MLlib, Scikit-learn, PyTorch, Keras, TensorFlow

Preferred Experience •Several Scientific publications on ’omics or statistical genetics • Producer and/or maintainer of ’omic software publicly available • Experience in large science-driven organizations or consortia •Experience in international consortia • Participation in genetics, statistics, ’omics or bioinformatics meetings

Single-cell RNA-Sequencing (scRNA-Seq) is fast becoming a widespread technique for life science research. However, with more scRNA-Seq datasets deposited in public databases than ever before, it is important to ensure the integrity and reproducibility of the data. Find out how researchers from EMBL-EBI, University of California, Harvard Medical School, Wellcome Sanger Institute, University of Cambridge and other colleagues have put together guidelines for a minimum set of metadata needed for robust comparative analyses of scRNA-Seq. https://www.nature.com/articles/s41587-020-00744-z

blog comments powered by Disqus